Min Lu

Min Lu is an accomplished executive director of biology at Eli Lilly and Company, overseeing drug discovery efforts in fibrotic, cardio-renal, and metabolic conditions. With a robust background in clinical medicine and pathophysiology, they have successfully led teams in preclinical and translational research, notably developing novel drug candidates and biomarker strategies. Min has also held senior positions at various biotech firms, including Pfizer and Merck, and has published extensively in major peer-reviewed journals. They earned a PhD in Biomedical Science from the University of California, Riverside, and an MD in Clinical Medicine.